IBT_B: Phase 3 trial for IBP-9414 completed; results expected Q3 2024 amid higher H1 losses

About this update from Infant Bacterial Therapeutics Ab Class B

IBT reported a larger operating loss in H1 2024 as it completed its pivotal Phase 3 trial for IBP-9414, with results expected in Q3 2024. Cash reserves remain strong, and regulatory and commercial preparations are underway.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Infant Bacterial Therapeutics Ab Class B